{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-024752","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.018210+00:00","generated_at":"2026-05-15T18:49:39.859496+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"InMed to wind down BayMedica commercial ops; focus shifts to Alzheimer's, AMD pipeline","bullets":["Board ratified wind-down of BayMedica commercial operations due to H.R. 5371 uncertainty; completion expected by June 30, 2026.","Estimated severance costs of ~$550K and other expenses ~$120K; partially offset by product sale profits during wind-down.","Company will focus exclusively on INM-901 (Alzheimer's) and INM-089 (dry AMD) drug candidates; commercial revenue stream eliminated.","Pro forma financial statements treat BayMedica as discontinued operations; revenue from commercial ops reduced to $0."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-024752","json":"https://secwatch.observer/filing/0001213900-26-024752.json","markdown":"https://secwatch.observer/filing/0001213900-26-024752.md","text":"https://secwatch.observer/filing/0001213900-26-024752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026024752/0001213900-26-024752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026024752/ea0279869-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:49:39.859496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6ba4a45c949c2489b920e25c5e7d22f9d7dd578","claim":"InMed Pharmaceuticals Inc. announced a restructuring with charges of severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000 affecting BayMedica LLC commercial operations business segment.","evidence_excerpt":"In connection with the wind down of commercial operations, BayMedica is expected to incur severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000 through the end of the fiscal year.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026024752/0001213900-26-024752-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000"},{"label":"Affected area","value":"BayMedica LLC commercial operations business segment"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}